Article Text

Download PDFPDF
Ultrasound-Guided Percutaneous Radiofrequency Ablation of Liver Metastasis From Ovarian Cancer: A Single-Center Initial Experience
  1. Baoxian Liu, MD, PhD*,
  2. Guangliang Huang, MD, PhD*,
  3. Chunlin Jiang, MD*,
  4. Ming Xu, MD, PhD*,
  5. Bowen Zhuang, MD*,
  6. Manxia Lin, MD*,
  7. Wenshuo Tian, MD, PhD*,
  8. Xiaohua Xie, MD, PhD*,
  9. Ming Kuang, MD, PhD*, and
  10. Xiaoyan Xie, MD, PhD*
  1. * Division of Interventional Ultrasound, Department of Medical Ultrasound, and
  2. Department of Liver Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
  1. Address correspondence and reprint requests to Xiaoyan Xie, MD, PhD, Division of Interventional Ultrasound, Department of Medical Ultrasound, The First Affiliated Hospital of Sun Yat-sen University, 58 Zhong Shan Road 2, Guangzhou, 510080, China. E-mail: xiexy1992{at}126.com; or Ming Kuang, MD, PhD, Division of Interventional Ultrasound, Department of Liver Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, China. E-mail: kuangm{at}mail.sysu.edu.cn.

Abstract

Objective The aim of this study was to evaluate the feasibility, effectiveness, and safety of ultrasound-guided percutaneous radiofrequency ablation (RFA) for the treatment of liver metastasis from ovarian cancer (OC).

Methods A retrospective review was performed on 11 patients (mean age, 53.0 ± 10.1 years) with 22 liver metastases (mean diameter, 2.0 ± 0.8 cm) from OC undergone RFA. Radiofrequency ablation was carried out with Starburst XL electrodes (RITA Medical System, Mountain View, CA) or Cool-tip electrodes (Cool-tip Systems; Valleylab, Boulder, CO). The tumor response, time to progression, and survival after RFA were assessed.

Results Complete ablation was achieved for all lesions. The technique effectiveness was 100%. During the follow-up period, local tumor progression was observed in 1 (4.5%) of 22 lesions. The median time to progression was 8.0 months after RFA. Three patients died because of disease progression after 13, 18, and 24 months, respectively. The mean overall survival time after RFA was 53.1 ± 10.0 months, with the 1-, 3-, and 5-year overall survival rates of 100%, 61%, and 61%, respectively. No major complications were encountered.

Conclusions Radiofrequency ablation as an alternative treatment strategy is feasible and effective for selected patients with liver metastasis from OC, providing a high rate of local tumor control.

  • Liver metastasis
  • Local tumor control
  • Ovarian cancer
  • Radiofrequency ablation

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • The authors have no conflict of interest.